Conclusion, Investment Implications, Strategy

The iShares Biotechnology ETF (IBB) is in the midst of a May 2nd major uptrend as defined by its 200-day moving average amid monthly asset expansion and quarterly relative outperformance versus the benchmark S&P 500 (SPX).  Together, these factors establish favorable conditions for continued strength. 

IBB Poised For More Outright Strength, Relative Outperformance

The upper panel of Chart 1 below shows that the iShares Biotechnology ETF (IBB) is in the midst of a May 2nd major uptrend as defined by its 200-day moving average.  The middle panel shows that the total net assets (AUM) invested in IBB rose above their 21-day moving average on Jly 9th to indicate a Tactical trend of expansion, characteristic of sustainable minor price advances.  The lower panel shows that IBB has been outperforming the benchmark S&P 500 (SPX) on a Strategic quarterly basis since Jly 16th. 

As long as these three conditions remain true, the price of IBB is likely to continue moving higher in the weeks ahead.

Chart 1

Current Sector & Industry Group Ideas

Table 1 below is also accessible via the Asbury ETF Trade Ideas rectangle at the top of the Research Center.

Table 1

Click the table to make it larger